Press Releases Latest May 10, 2022 Appointments in Conjunction With Theratechnologies Annual Meeting Press Releases Year None2022202120202019201820172016201520142013 May 10, 2022 Appointments in Conjunction With Theratechnologies Annual Meeting May 10, 2022 Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies Apr 27, 2022 Theratechnologies to Focus Its Commercialization Activities on the North American Territory Apr 25, 2022 Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022 Apr 13, 2022 Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update Apr 08, 2022 Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR Annual Meeting 2022 Mar 31, 2022 Theratechnologies to Announce Financial Results for Its First Quarter 2022 Mar 08, 2022 Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers Feb 24, 2022 Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update Feb 16, 2022 Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022 Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 10 of 280
May 10, 2022 Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies
Apr 27, 2022 Theratechnologies to Focus Its Commercialization Activities on the North American Territory
Apr 13, 2022 Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update
Apr 08, 2022 Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR Annual Meeting 2022
Mar 08, 2022 Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers
Feb 24, 2022 Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update
Feb 16, 2022 Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022
